CTSO

CytoSorbentsF

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$0.70

Analysis reference price unavailable

Analysis 2026-07-01 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.30

Analysis reference price unavailable

Analysis 2026-07-01 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.15

Analysis reference price unavailable

Analysis 2026-07-01 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-01

AI commentary

Primary-source evidence improved versus the prior baseline because the company provided a fresh June 24 regulatory update and a detailed May 13 earnings release, but the overall setup still looks like a cautious monitoring case, not a clean turnaround. The deterministic prior turned negative, the stock remained at $0.374 on June 30, 2026, and I did not verify a trustworthy post-print analyst-revision set or durable positive market-reaction signal, so confidence should stay moderate rather than aggressive.

RankAlpha Sentiment Codex - 2026-07-01

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-31eventAugust 2026 FDA pre-submission meetings on ticagrelor and DOAC programsHigh impact

CytoSorbents disclosed on June 24, 2026 that it scheduled two FDA pre-submission meetings in August 2026 to discuss its ticagrelor and DOAC programs, making regulatory feedback the clearest near-term operating catalyst after the Q1 update [#8-K-2026-06-25].

2026-09-28eventNasdaq minimum-bid compliance deadline remains a hard equity overhangHigh impact

Nasdaq gave CTSO until September 28, 2026 to regain compliance with the $1.00 minimum bid requirement; with the anchor price still at $0.374 on June 30, 2026, the stock remains exposed to reverse-split or listing-risk headlines if it cannot sustain a recovery [#8-K-2026-04-02].

2026-12-31catalystLiquidity stabilization must offset going-concern pressureHigh impact

Q1 revenue rose only 2% to $8.9 million, cash fell to about $6.4 million, and management said additional capital may be needed if operating improvements and regulatory milestones do not arrive fast enough; that keeps financing execution and cash-burn control central to the thesis [#SEC-8K-2026-05-13] [#10-Q-2026-05-13].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-01 • Updated nightlySource: Internal modelMethodology